| References |
| 1 |
Canadian Pharmacists Association.
|
| 2 |
Cerner Multum, Inc. "Australian Product Information.".
|
| 3 |
Cerner Multum, Inc. "UK Summary of Product Characteristics.".
|
| 4 |
Hatta K, Takahashi T, Nakamura H, Yamashiro H, Asukai N, Matsuzaki I, Yonezawa Y "The association between intravenous haloperidol and prolonged QT interval." J Clin Psychopharmacol 21 (2001): 257-61. [PMID: 11386487]
|
| 5 |
Huyse F, van Schijndel RS "Haloperidol and cardiac arrest." Lancet 2 (1988): 568-9. [PMID: 2900948]
|
| 6 |
Metzger E, Friedman R "Prolongation of the corrected QT and torsades de pointes cardiac arrhythmia associated with intravenous haloperidol in the medically ill." J Clin Psychopharmacol 13 (1993): 128-32. [PMID: 8463445]
|
| 7 |
O'Brien JM, Rockwood RP, Suh KI "Haloperidol-induced torsade de pointes." Ann Pharmacother 33 (1999): 1046-9. [PMID: 10534216]
|
| 8 |
Product Information. Haldol (haloperidol). McNeil Pharmaceutical, Raritan, NJ.
|
| 9 |
Wilt JL, Minnema AM, Johnson RF, Rosenblum AM "Torsade de pointes associated with the use of intravenous haloperidol." Ann Intern Med 119 (1993): 391-4. [PMID: 8338292]
|
| 10 |
EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
|